Medexus Pharmaceuticals Inc. (MEDXF) Stock

About Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc. is a specialized pharmaceutical firm conducting operations across both Canada and the United States. The company's therapeutic focus spans several critical domains, including cancer treatment (oncology), blood disorders (hematology), joint and muscle conditions (rheumatology), autoimmune disorders, and allergic reactions. Among its leading offerings are Rasuvo and Metoject, both methotrexate formulations specifically developed for managing rheumatoid arthritis and various autoimmune conditions. Another significant product is IXINITY, an intravenous recombinant factor IX therapy prescribed for individuals aged 12 and above suffering from Hemophilia B. Additionally, Rupall serves as a prescription medication for allergies. The company's diverse product lineup further comprises Treosulfan, a bifunctional alkylating agent utilized in allogeneic hematopoietic stem cell transplants; Trispan, an injectable suspension of triamcinolone hexacetonide; and Gleolan, an optical imaging agent indicated for patients presenting with symptoms of glioma. Previously known as Pediapharm Inc., the company adopted its current name, Medexus Pharmaceuticals Inc., in December 2018. Its corporate headquarters are situated in Bolton, Canada.

Medexus Pharmaceuticals Inc. is headquartered in CA.

Medexus Pharmaceuticals Inc. (MEDXF) stock trades at $3.55 with a market capitalization of $112.46M. The stock is valued at a price-to-earnings (P/E) ratio of -46.18, price-to-book of 2.34, price-to-sales of 1.14. Over the past 52 weeks the stock has ranged between $1.80 and $3.69, and currently trades 3.8% below its 52-week high.

On profitability, Medexus Pharmaceuticals Inc. generates a return on equity (ROE) of -4.64%, return on capital employed of 5.96%, an operating margin of 5.62%, a net profit margin of -2.41%.

Official website: www.medexus.com